In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Torcetrapib: Biomarker for the Big Pharma Business Model

Executive Summary

As biotechs often live or die on the success of one pipeline project, so too Pfizer finds itself in the same position. Weak drug launches, intense competition in its core cholesterol franchise, and, analysts say, an unimpressive pipeline. Except torcetrapib--perhaps the most important clinical-stage project in the industry. If it fails, Pfizer's in trouble. If it succeeds, Pfizer will have proven that giantism isn't antithetical to growth.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel